A real-world study of camrelizumab in the treatment of advanced lung cancer patients.
Kangsheng Gu(Anhui Medical University), Zhiqiang Hu(Jiangsu University), Fan Wang(Nanfang Hospital), Xiaoyang Xia, Dong Zhao(Beijing University of Chemical Technology), Huaidong Cheng(Anhui Medical University), Hong Qian(Anqing City Hospital), Xuhong Min(Xi'an Chest Hospital), Minghong Bi(First Affiliated Hospital of Bengbu Medical College), Genhe Wang(Huangshan University)
Cited by 2
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Noninvasive Imaging of CD206-Positive M2 Macrophages as an Early Biomarker for Post-Chemotherapy Tumor Relapse and Lymph Node Metastasis
|Theranostics|2017|111
Diagnostic, Therapeutic Predictive, and Prognostic Value of Neutrophil Extracellular Traps in Patients With Gastric Adenocarcinoma
|Frontiers in Oncology|2020|79
Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing
|Journal of Experimental & Clinical Cancer Research|2016|69
“Learning” Can Improve the Blood Glucose Control Performance for Type 1 Diabetes Mellitus
|Diabetes Technology & Therapeutics|2017|54